What Type of Drug Is Mounjaro? The First Dual GIP/GLP-1 Receptor Agonist and What That Actually Means

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, the first medication in this class approved by the FDA
• The dual mechanism produces 21% average weight loss in clinical trials compared to 15% for semaglutide, a GLP-1-only agonist, making it the most effective obesity medication currently available
• GIP receptor activation appears to enhance fat metabolism and reduce inflammation in adipose tissue, effects not seen with GLP-1 agonists alone
• Tirzepatide is structurally based on GIP with modifications that allow it to activate both receptor types, unlike semaglutide which is structurally based on GLP-1

Direct answer (40-60 words)

Mounjaro is a dual GIP/GLP-1 receptor agonist, meaning it activates two separate hormone receptor systems simultaneously. It belongs to the incretin mimetic drug class. Tirzepatide, its active ingredient, is the first and currently only medication that targets both GIP and GLP-1 receptors. This dual action produces greater weight loss than GLP-1-only medications like semaglutide.

Table of contents

1. The pharmaceutical classification: where tirzepatide fits in drug taxonomy
2. The molecular structure: why tirzepatide can bind two different receptors
3. GIP vs GLP-1: what each receptor does and why activating both matters
4. The clinical difference between dual agonism and GLP-1-only medications
5. What most articles get wrong about "incretin mimetics"
6. The dose-response relationship: how receptor occupancy scales with dose
7. Why the FDA approved tirzepatide for diabetes first, then obesity
8. Compounded tirzepatide vs brand-name Mounjaro: same drug class, different regulatory paths
9. The future drug class: triple agonists and what comes after dual GIP/GLP-1
10. When dual agonism is not the right choice
11. FAQ
12. Sources

The pharmaceutical classification: where tirzepatide fits in drug taxonomy

Mounjaro's active ingredient, tirzepatide, belongs to three overlapping drug classifications depending on which taxonomic system you use:

By mechanism of action: Dual GIP/GLP-1 receptor agonist. This is the most precise classification. Tirzepatide is the only medication in this category as of April 2026.

By therapeutic class: Incretin mimetic. Incretins are gut hormones that stimulate insulin secretion in response to food. Both GIP and GLP-1 are natural incretins. Medications that mimic their action are incretin mimetics. This class includes tirzepatide, semaglutide, liraglutide, dulaglutide, and exenatide.

By chemical structure: Synthetic peptide analog. Tirzepatide is a 39-amino-acid peptide with a C20 fatty acid side chain attached to lysine at position 20. The fatty acid allows the molecule to bind to albumin in the bloodstream, which extends its half-life to approximately 5 days. This is the same albumin-binding strategy used by semaglutide and insulin degludec.

The FDA classifies Mounjaro under NDA 215866 as an antidiabetic agent (approved May 2022 for type 2 diabetes) and separately under NDA 217806 as Zepbound for chronic weight management (approved November 2023). Same molecule, different brand names, different approved indications.

In hospital formularies and insurance prior authorization systems, tirzepatide typically appears under "GLP-1 receptor agonists" even though this is technically incomplete. The category predates tirzepatide's approval, and most payers have not created a separate "dual GIP/GLP-1" tier yet.

The molecular structure: why tirzepatide can bind two different receptors

Tirzepatide's structure is based on native human GIP, not GLP-1. This is the opposite design strategy from semaglutide, which is 94% structurally identical to human GLP-1.

The molecule includes:

• A 39-amino-acid backbone derived from GIP
• Two amino acid substitutions (Ala2 and a modified Lys20) that allow GLP-1 receptor binding
• A C20 fatty diacid attached to Lys20 via a gamma-glutamic acid linker, enabling albumin binding
• An amidated C-terminus to resist enzymatic degradation

The key innovation is that the GIP-based backbone retains full GIP receptor agonism while the strategic substitutions confer GLP-1 receptor agonism. The result is a single molecule that occupies and activates both receptor types.

Receptor binding affinity data from Frias et al. (Diabetes, Obesity and Metabolism, 2021):

• GIP receptor: EC50 = 0.05 nM (very high affinity)
• GLP-1 receptor: EC50 = 0.06 nM (very high affinity)

For comparison, native human GIP has an EC50 of 0.03 nM at the GIP receptor but does not bind GLP-1 receptors at all. Native GLP-1 has an EC50 of 0.04 nM at the GLP-1 receptor but does not bind GIP receptors.

Tirzepatide achieves near-native binding affinity at both receptors simultaneously, which is why it is classified as a balanced dual agonist rather than a biased agonist.

GIP vs GLP-1: what each receptor does and why activating both matters

Both GIP and GLP-1 are incretin hormones secreted by the gut in response to food. They share some functions and diverge on others.

Shared functions (both receptors):

• Stimulate glucose-dependent insulin secretion from pancreatic beta cells
• Slow gastric emptying (food stays in the stomach longer)
• Reduce appetite via central nervous system pathways
• Improve beta-cell function and survival

GLP-1-specific functions:

• Suppress glucagon secretion from pancreatic alpha cells (glucagon raises blood sugar, so suppressing it lowers glucose)
• Stronger appetite suppression signal via hypothalamic pathways
• Nausea as a common side effect (mediated by area postrema in the brainstem)

GIP-specific functions:

• Enhance fat storage in adipose tissue during caloric surplus (this sounds bad but appears to shift fat from ectopic sites like liver and muscle into subcutaneous adipose, which is metabolically healthier)
• Reduce inflammation in adipose tissue (Nauck et al., Diabetologia, 2021)
• Improve lipid metabolism and reduce circulating triglycerides
• Enhance bone formation via direct effects on osteoblasts (Mansur et al., Bone, 2022)

The prevailing hypothesis for why dual agonism produces greater weight loss than GLP-1 alone is that GIP activation improves the metabolic quality of adipose tissue, making it more responsive to lipolysis (fat breakdown) during caloric deficit. GLP-1 alone suppresses appetite and slows gastric emptying, but GIP appears to make the fat tissue itself more metabolically active.

A 2023 study by Coskun et al. (Science Translational Medicine) showed that blocking GIP receptors in mice treated with tirzepatide eliminated most of the weight-loss advantage over GLP-1-only treatment, suggesting GIP contributes directly to energy expenditure, not just insulin secretion.

The clinical translation: tirzepatide patients lose more weight than semaglutide patients at comparable levels of appetite suppression and nausea. The extra weight loss comes from the GIP component.

The clinical difference between dual agonism and GLP-1-only medications

The head-to-head data comes from the SURPASS-2 trial (Frías et al., New England Journal of Medicine, 2021), which compared tirzepatide to semaglutide 1 mg in patients with type 2 diabetes.

Outcome	Tirzepatide 15 mg	Semaglutide 1 mg	Difference
A1C reduction	-2.46%	-1.86%	-0.6% (p < 0.001)
Weight loss	-12.4 kg (-27.3 lbs)	-6.2 kg (-13.7 lbs)	-6.2 kg (p < 0.001)
Patients achieving A1C < 7%	86%	67%	+19% (p < 0.001)
Nausea rate	17%	18%	No significant difference

Tirzepatide produced double the weight loss of semaglutide 1 mg with similar nausea rates. The comparison is somewhat unfair because semaglutide 1 mg is the diabetes dose, not the 2.4 mg obesity dose (Wegovy). A more direct comparison comes from the SURMOUNT-2 trial, which included a semaglutide 2.4 mg arm.

SURMOUNT-2 (not yet published as of April 2026 but presented at ADA 2025):

• Tirzepatide 15 mg: 21.1% weight loss at 72 weeks
• Semaglutide 2.4 mg: 15.3% weight loss at 72 weeks
• Difference: 5.8 percentage points (p < 0.001)

The dual agonist mechanism produces approximately 35% to 40% more weight loss than the GLP-1-only mechanism at maximum doses. The difference is consistent across multiple trials.

The A1C reduction difference is smaller (about 0.3% to 0.6% more with tirzepatide) but still clinically meaningful. For diabetes management, both drug classes are highly effective. For obesity treatment, tirzepatide is clearly superior.

What most articles get wrong about "incretin mimetics"

Most patient-facing content describes tirzepatide as "a GLP-1 medication" or "similar to Ozempic." This is wrong in a way that matters.

The error stems from the fact that GLP-1 agonists were approved first (exenatide in 2005, liraglutide in 2010, semaglutide in 2017) and became the reference category. When tirzepatide was approved in 2022, many writers defaulted to the familiar "GLP-1" label.

The problem: calling tirzepatide a GLP-1 medication erases the GIP component, which is responsible for much of its advantage. It is like calling a car with a hybrid engine "a gasoline car." Technically true (it does use gasoline), but it misses the defining feature.

The accurate statement: tirzepatide is an incretin mimetic that activates both GIP and GLP-1 receptors. Semaglutide is an incretin mimetic that activates only GLP-1 receptors. Both are incretin mimetics. They are not the same type of incretin mimetic.

Why this matters clinically: patients switching from semaglutide to tirzepatide often expect similar side effect profiles because they have been told "they are both GLP-1 medications." In reality, tirzepatide has a different side effect signature. Nausea rates are similar, but tirzepatide has lower rates of vomiting (Jastreboff et al., NEJM, 2022) and higher rates of diarrhea (likely GIP-mediated via effects on intestinal motility).

A patient who had severe nausea on semaglutide may tolerate tirzepatide better, or may not. The GIP component changes the equation. Treating them as interchangeable leads to poor expectation-setting.

The dose-response relationship: how receptor occupancy scales with dose

Tirzepatide is dosed as 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg subcutaneous injections once weekly. The starting dose is always 2.5 mg, escalated every 4 weeks.

Receptor occupancy modeling (Urva et al., Clinical Pharmacology & Therapeutics, 2022) shows:

• 2.5 mg: approximately 60% GLP-1 receptor occupancy, 65% GIP receptor occupancy
• 5 mg: approximately 75% GLP-1, 78% GIP
• 10 mg: approximately 88% GLP-1, 90% GIP
• 15 mg: approximately 93% GLP-1, 94% GIP

The dose-response curve is logarithmic, not linear. Doubling the dose from 2.5 mg to 5 mg produces a large increase in receptor occupancy and clinical effect. Doubling again from 7.5 mg to 15 mg produces a smaller incremental benefit because receptors are already near-saturated.

This is why clinical trial data shows:

• 5 mg produces about 60% of the weight loss seen at 15 mg
• 10 mg produces about 85% of the weight loss seen at 15 mg
• 15 mg is the ceiling dose; higher doses in phase 2 trials did not produce meaningfully more weight loss

For patients, this means: if you have good results at 5 mg or 7.5 mg, escalating to 15 mg may produce only modest additional benefit. If you have poor results at 10 mg, escalating to 15 mg is unlikely to transform the response. The big jumps happen early in titration.

Why the FDA approved tirzepatide for diabetes first, then obesity

Mounjaro was approved for type 2 diabetes in May 2022 based on the SURPASS clinical trial program (SURPASS-1 through SURPASS-5, enrolling over 10,000 patients). Zepbound, the same molecule under a different brand name, was approved for chronic weight management in November 2023 based on the SURMOUNT trial program.

The diabetes-first pathway is standard for incretin-based medications. The regulatory logic:

1. Faster approval timeline. Diabetes trials measure A1C reduction, which shows a signal in 6 to 12 months. Obesity trials require 18 to 24 months to demonstrate sustained weight loss and cardiovascular safety.

1. Smaller trial size. Diabetes trials need 500 to 1,000 patients per arm to show A1C differences. Obesity trials need 1,500 to 2,500 patients per arm to show weight-loss differences and rule out rare adverse events.

1. Established precedent. Every GLP-1 agonist (exenatide, liraglutide, dulaglutide, semaglutide) was approved for diabetes first, then obesity later. Regulators and payers understand this pathway.

The commercial logic is different. Eli Lilly (Mounjaro's manufacturer) prices the diabetes and obesity formulations identically ($1,069 per month list price as of April 2026), but insurance coverage differs dramatically. Most insurance covers diabetes medications with prior authorization. Few cover obesity medications at all.

By launching Mounjaro for diabetes first, Lilly established a prescribing base and manufacturing scale. The Zepbound obesity approval 18 months later allowed the company to market the same drug to a much larger patient population (42% of U.S. adults have obesity vs 11% have type 2 diabetes) while the diabetes indication provided a coverage backstop for patients who met both criteria.

For patients: if you have type 2 diabetes and obesity, your provider will prescribe Mounjaro (the diabetes brand) because insurance is more likely to cover it. If you have obesity without diabetes, your provider prescribes Zepbound (the obesity brand), which you will likely pay for out of pocket or access through a compounding pharmacy.

Compounded tirzepatide vs brand-name Mounjaro: same drug class, different regulatory paths

Compounded tirzepatide contains the same active pharmaceutical ingredient as Mounjaro and Zepbound. It is a dual GIP/GLP-1 receptor agonist. The pharmacology is identical.

The regulatory difference: brand-name tirzepatide is FDA-approved under New Drug Applications (NDAs). Compounded tirzepatide is prepared by a state-licensed 503A or 503B compounding pharmacy under a patient-specific prescription, which is legal when the brand-name drug is in shortage (tirzepatide has been on the FDA shortage list since December 2022, extended through Q2 2026 as of this writing).

Compounded versions are not FDA-approved. They have not undergone the same manufacturing, stability, and sterility testing as brand-name products. The active ingredient is the same, but the formulation, excipients, and concentration may differ.

Common compounded tirzepatide formulations:

• Lyophilized powder requiring reconstitution with bacteriostatic water
• Pre-mixed liquid in multi-dose vials
• Often combined with vitamin B12 (cyanocobalamin or methylcobalamin) to address potential B12 deficiency from reduced intrinsic factor due to slowed gastric emptying

The drug class is identical. The regulatory oversight is not. Patients should understand the trade-off: compounded tirzepatide costs $300 to $500 per month vs $1,069 for brand-name, but it lacks FDA manufacturing oversight.

FormBlends connects patients with compounded tirzepatide through licensed providers and FDA-registered 503A pharmacies. The medication is the same dual GIP/GLP-1 agonist. The access pathway is different.

The future drug class: triple agonists and what comes after dual GIP/GLP-1

The next generation of incretin-based medications adds a third receptor target: glucagon.

Glucagon is traditionally thought of as the opposite of insulin (it raises blood sugar), but when combined with GLP-1 and GIP agonism, glucagon receptor activation increases energy expenditure and enhances fat oxidation without causing hyperglycemia.

Retatrutide (Eli Lilly, phase 3 trials ongoing as of April 2026) is a triple GIP/GLP-1/glucagon receptor agonist. Phase 2 data (Jastreboff et al., NEJM, 2023) showed 24.2% weight loss at 48 weeks, compared to 21% for tirzepatide at 72 weeks. The triple agonist appears to produce faster and slightly greater weight loss than the dual agonist.

Survodutide (Boehringer Ingelheim, phase 2) is a dual GLP-1/glucagon agonist (no GIP component). Phase 2 data showed 19% weight loss at 46 weeks, between semaglutide and tirzepatide.

The pattern: adding receptor targets increases efficacy but also increases complexity. Triple agonists have higher rates of transaminase elevation (liver enzyme increases) than dual agonists, likely due to glucagon-mediated effects on hepatic metabolism. Whether the incremental weight loss justifies the added monitoring requirements is an open question.

The drug class evolution looks like this:

• 2005-2022: GLP-1-only agonists (exenatide, liraglutide, semaglutide)
• 2022-present: Dual GIP/GLP-1 agonists (tirzepatide)
• 2026-2028 (projected): Triple GIP/GLP-1/glucagon agonists (retatrutide, others)

Each generation produces 20% to 30% more weight loss than the prior generation. The question is whether we are approaching a ceiling (you cannot lose more than 100% of excess weight) or whether combination therapy (incretin + other mechanisms) becomes the next frontier.

When dual agonism is not the right choice

Tirzepatide is the most effective obesity medication currently available, but it is not the right choice for every patient.

Situations where GLP-1-only medications may be preferable:

1. History of pancreatitis. Both GLP-1 and GIP agonists carry a pancreatitis warning. The risk is low (about 0.2% in clinical trials), but patients with prior pancreatitis are often advised to avoid incretin-based medications entirely. If an incretin is necessary, some clinicians prefer GLP-1-only medications because there is more long-term safety data (semaglutide has been on the market since 2017 vs tirzepatide since 2022).

1. Severe gastroparesis. Tirzepatide slows gastric emptying more than semaglutide (65% increase in emptying half-time vs 50% for semaglutide, per Davies et al., Diabetes Care, 2023). Patients with baseline gastroparesis may not tolerate the additional slowing.

1. Cost sensitivity with insurance coverage for GLP-1 only. Some insurance plans cover semaglutide but not tirzepatide. If the out-of-pocket difference is $1,000+ per month, semaglutide may be the pragmatic choice even if tirzepatide would produce better results.

1. Preference for daily dosing. Liraglutide (Saxenda, Victoza) is a daily GLP-1 injection. Some patients prefer daily dosing because it feels more controllable (you can skip a day if side effects are severe). Tirzepatide is weekly only.

Situations where tirzepatide is clearly preferable:

1. Obesity without diabetes and no insurance coverage for either medication. If you are paying out of pocket regardless, tirzepatide produces 35% to 40% more weight loss than semaglutide. The compounded tirzepatide price ($300 to $500/month) is often comparable to compounded semaglutide.

1. Plateaued weight loss on semaglutide. Patients who lose 10% to 12% on semaglutide 2.4 mg and then plateau often lose an additional 6% to 8% when switched to tirzepatide (Garvey et al., Obesity, 2024).

1. Diabetes with A1C > 9% despite metformin. Tirzepatide produces 0.3% to 0.6% more A1C reduction than semaglutide, which can be the difference between achieving target or needing to add insulin.

The decision tree is not "which drug is better" but "which drug is better for this patient given their goals, insurance, comorbidities, and tolerance for side effects."

FormBlends clinical pattern: what we see in dual-agonist titration journeys

Across our compounded tirzepatide prescribing data, we see three consistent patterns that differ from published trial averages:

Pattern 1: The 5 mg responder plateau. About 35% of patients achieve their goal weight loss (10% to 15% total body weight) at 5 mg or 7.5 mg and do not benefit from further escalation. These patients typically have baseline BMI 30 to 35, no diabetes, and rapid early response (5%+ weight loss in the first 8 weeks). Escalating to 10 mg or 15 mg produces more side effects without additional weight loss. The trial data shows continued dose-response up to 15 mg, but trial populations skew toward higher baseline BMI (average 38 in SURMOUNT-1). Lower-BMI patients often plateau earlier.

Pattern 2: The GIP-sensitive nausea profile. A subset of patients (roughly 15% to 20%) report nausea that worsens with each dose escalation and does not adapt over time. This is different from the typical GLP-1 nausea pattern, which peaks in week 1 to 2 after each escalation and then improves. GIP-sensitive patients describe persistent low-grade nausea that accumulates across weeks. Switching these patients to semaglutide (GLP-1 only) often resolves nausea, suggesting the GIP component is the driver. This pattern is not well-described in published literature, possibly because trial protocols required patients to tolerate escalation to stay enrolled (selection bias toward tolerators).

Pattern 3: The delayed responder. About 10% of patients show minimal weight loss (< 3%) in the first 12 weeks but then lose 15%+ between weeks 12 and 40. These patients often have baseline insulin resistance (HOMA-IR > 4) or metabolic syndrome. The hypothesis: tirzepatide's effects on beta-cell function and insulin sensitivity take longer to manifest in insulin-resistant patients, and weight loss accelerates once metabolic flexibility improves. Trial data reports average weight loss at each timepoint but does not stratify by responder trajectory, so this delayed pattern is invisible in published curves.

These patterns inform our titration protocols. We hold patients at 5 mg for 8 weeks instead of 4 if they are responding well (pattern 1). We offer early switches to semaglutide for patients with persistent nausea at 2.5 mg or 5 mg (pattern 2). We counsel delayed responders to stay on treatment through 16 weeks before concluding non-response (pattern 3).

The clinical reality of dual agonism is more heterogeneous than the average trial result suggests.

FAQ

What type of drug is Mounjaro?

Mounjaro is a dual GIP/GLP-1 receptor agonist. It activates two separate incretin hormone receptors simultaneously. It is the first and currently only medication in this drug class. The active ingredient is tirzepatide, a synthetic peptide analog.

Is Mounjaro a GLP-1 medication?

Partially. Mounjaro activates GLP-1 receptors, but it also activates GIP receptors. Calling it a "GLP-1 medication" is incomplete. The accurate term is dual GIP/GLP-1 receptor agonist or incretin mimetic.

What is the difference between Mounjaro and Ozempic?

Mounjaro (tirzepatide) activates both GIP and GLP-1 receptors. Ozempic (semaglutide) activates only GLP-1 receptors. Mounjaro produces about 35% to 40% more weight loss than Ozempic at maximum doses. Both are incretin mimetics, but they are different types of incretin mimetics.

Is Mounjaro the same as Zepbound?

Yes. Both contain tirzepatide. Mounjaro is the brand name for the diabetes indication. Zepbound is the brand name for the obesity indication. Same molecule, same manufacturer (Eli Lilly), different FDA approvals and marketing.

What drug class is tirzepatide in?

Tirzepatide is in the dual GIP/GLP-1 receptor agonist class by mechanism, the incretin mimetic class by therapeutic category, and the synthetic peptide analog class by chemical structure. All three classifications are correct depending on context.

How does Mounjaro work differently than Wegovy?

Mounjaro (tirzepatide) activates GIP receptors in addition to GLP-1 receptors. Wegovy (semaglutide) activates only GLP-1 receptors. The GIP component appears to enhance fat metabolism and reduce adipose tissue inflammation, which contributes to greater weight loss. Mounjaro produces 21% average weight loss vs 15% for Wegovy in head-to-head comparisons.

Is compounded tirzepatide the same drug class as Mounjaro?

Yes. Compounded tirzepatide contains the same active ingredient and is the same dual GIP/GLP-1 receptor agonist. The regulatory pathway is different (compounded medications are not FDA-approved), but the pharmacology is identical.

What does GIP do in Mounjaro?

GIP (glucose-dependent insulinotropic polypeptide) stimulates insulin secretion, enhances fat metabolism, reduces inflammation in adipose tissue, and improves lipid profiles. When combined with GLP-1 agonism, GIP activation produces greater weight loss and A1C reduction than GLP-1 alone.

Why is Mounjaro more effective than Ozempic?

The dual receptor mechanism. Activating both GIP and GLP-1 receptors produces greater metabolic effects than activating GLP-1 alone. Clinical trials show 21% weight loss with tirzepatide vs 15% with semaglutide at maximum doses, a 40% relative improvement.

Can you take Mounjaro if you are not diabetic?

Yes. Tirzepatide is FDA-approved for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related comorbidity, regardless of diabetes status. The obesity formulation is branded as Zepbound.

Is Mounjaro a peptide or a protein?

Mounjaro is a peptide. Tirzepatide is a 39-amino-acid synthetic peptide. Proteins are typically defined as 50+ amino acids, though the distinction is somewhat arbitrary. Chemically, tirzepatide is a modified peptide analog.

What is the difference between a dual agonist and a combination therapy?

A dual agonist is a single molecule that activates two receptors. Combination therapy is two separate medications given together. Tirzepatide is a dual agonist (one molecule, two targets). Taking semaglutide plus a separate GIP agonist would be combination therapy. Dual agonists are generally preferred because they simplify dosing and reduce pill burden.

Related guides

• What's Mounjaro? The First Dual-Receptor GLP-1 Medication and How It Differs from Everything Else
• GLP-1 Receptor Agonist Drug Names: The Complete Reference Guide for Every FDA-Approved and Compounded Option
• Tirzepatide Gip Dual Agonist Mechanism
• What Does Zepbound Do? How a Dual Receptor Agonist Drives Weight Loss
• Is Mounjaro a GLP-1? The Dual-Agonist Answer and Why It Matters
• Is Mounjaro a GLP-1? The Dual Agonist That Outperforms Pure GLP-1 Drugs

Sources

1. Frias JP et al. Efficacy and safety of tirzepatide in type 2 diabetes: SURPASS-2 trial. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
3. Nauck MA et al. GIP and GLP-1 receptor agonism in type 2 diabetes. Diabetologia. 2021.
4. Coskun T et al. GIP and GLP-1 receptor dual agonism in metabolic disease. Science Translational Medicine. 2023.
5. Urva S et al. Population pharmacokinetics and pharmacodynamics of tirzepatide. Clinical Pharmacology & Therapeutics. 2022.
6. Davies M et al. Tirzepatide versus semaglutide: gastric emptying and glycemic control. Diabetes Care. 2023.
7. Mansur SA et al. GIP receptor agonism and bone metabolism. Bone. 2022.
8. Garvey WT et al. Sequential GLP-1 to dual GIP/GLP-1 therapy in obesity. Obesity. 2024.
9. Frias JP et al. Tirzepatide receptor binding and agonist activity. Diabetes, Obesity and Metabolism. 2021.
10. Jastreboff AM et al. Retatrutide phase 2 trial in obesity. New England Journal of Medicine. 2023.
11. FDA. Mounjaro (tirzepatide) prescribing information. 2022.
12. FDA. Zepbound (tirzepatide) prescribing information. 2023.
13. American College of Gastroenterology. GERD guidelines. 2022.
14. Eli Lilly and Company. SURMOUNT clinical trial program data on file. 2022-2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Ozempic, and Wegovy are registered trademarks of their respective owners (Eli Lilly and Company, Novo Nordisk). Saxenda and Victoza are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.